Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant loss of -14.37% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -57.56%. Over the past 30 days, the price of MYGN has leaped by -8.42%. And in the last five days, it has fallen by -19.42%.
Myriad Genetics, Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $29.30 on 09/18/24 and the lowest value was $12.04 on 02/25/25.
52-week price history of MYGN Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Myriad Genetics, Inc’s current trading price is -59.93% away from its 52-week high, while its distance from the 52-week low is -2.49%. The stock’s price range during this period has varied between$12.04 and $29.30. The Myriad Genetics, Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.72 million for the day, a figure considerably higher than their average daily volume of 1.07 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Myriad Genetics, Inc (MYGN) has experienced a quarterly decline of -23.27% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.07B and boasts a workforce of 2700 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 16.61, with a change in price of -15.65. Similarly, Myriad Genetics, Inc recorded 998,049 in trading volume during the last 100 days, posting a change of -57.14%.
MYGN’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for MYGN stands at 0.20. Similarly, the long-term debt-to-equity ratio is also 0.18.
MYGN Stock Stochastic Average
As of today, Myriad Genetics, Inc’s raw stochastic average for the last 50 days stands at 34.68%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 34.68%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 48.48% and 63.60%, respectively.
